Publication|Articles|December 2, 2025
Supplements and Featured Publications
- The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
2
Heart Failure Deaths Shift to Home, Hospice, but Racial Disparities Persist
3
ICYMI: Highlights From ESMO 2025
4
Obstructive Sleep Apnea Identified as Potential Risk Factor for Parkinson Disease
5



































